Selective SGLT2 Inhibitors and Cardioprotection in Non-Diabetic Mice: Mechanistic Insights and Translational Relevance

Study Background and Research Question

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a mainstay in the management of type 2 diabetes mellitus (T2D) due to their ability to block renal glucose reabsorption and promote glycosuria. Beyond glycemic control, clinical trials have indicated these agents reduce heart failure events and improve cardiovascular outcomes in patients with and without diabetes. However, it is unclear whether these cardiovascular effects represent a class effect or are molecule-specific. The reference study (Basic Research in Cardiology, 2022) investigates this question by directly comparing empagliflozin, dapagliflozin, and ertugliflozin (PF-04971729) for their ability to reduce myocardial infarct size and elucidates the molecular mechanisms underlying potential cardioprotection in non-diabetic mice.

Key Innovation from the Reference Study

The core innovation of this work is its head-to-head comparison of three SGLT2 inhibitors in a controlled, non-diabetic animal model of acute myocardial ischemia/reperfusion (I/R) injury. By using stoichiometrically equivalent dosing and rigorous mechanistic assays—including advanced proteomics, mitochondrial respiration analysis, and pharmacological pathway inhibition—the study dissects whether SGLT2 inhibition per se or specific molecular actions of individual drugs confer cardioprotection. This distinguishes drug-specific effects from those attributable to the class, offering clarity for translational strategies in cardiovascular research and therapy.

Methods and Experimental Design Insights

• Animal Model: Adult male C57BL/6 mice were randomized to receive vehicle, empagliflozin (10 mg/kg/day), dapagliflozin, or ertugliflozin at stoichiometrically equivalent doses (SED) via oral gavage for 7 days.
• Verification of SGLT2 Inhibition: Urinary glucose excretion was assessed over 24 hours post-treatment to confirm pharmacodynamic inhibition of SGLT2-mediated glucose transport.
• Ischemia/Reperfusion Protocol: Myocardial I/R injury was induced via 30 minutes of left anterior descending (LAD) coronary artery occlusion followed by 120 minutes of reperfusion. Infarct size (IS) was quantified relative to the area at risk.
• Mechanistic Analyses: Mitochondrial oxidative phosphorylation (OXPHOS) and fatty acid oxidation (FAO) rates were measured via high-resolution respirometry. Shotgun proteomics characterized protein expression changes. Inhibitors of STAT-3 (Stattic) and PI3K (wortmannin) were employed to interrogate downstream signaling.
• Dose Escalation: Ertugliflozin was also tested at double the SED (20 mg/kg/day) to assess dose-dependency of effects.

Core Findings and Why They Matter

All three SGLT2 inhibitors induced marked urinary glucose excretion, confirming robust inhibition of renal glucose reabsorption. However, only empagliflozin and dapagliflozin significantly reduced myocardial infarct size at the SED; ertugliflozin did not exhibit infarct-sparing effects at this dose. Notably, ertugliflozin reduced infarct size only when administered at twice the SED (20 mg/kg/day), indicating a higher threshold for efficacy in this context (reference study).

Mechanistically, empagliflozin preserved mitochondrial function during I/R injury, maintaining complex I & II-linked OXPHOS. Both empagliflozin and dapagliflozin activated key prosurvival signaling pathways—NF-κB, RISK, and STAT-3—and increased expression of fibroblast growth factor-2 (FGF-2) and caveolin-3 (Cav-3), with resultant reduction in apoptosis. Administration of STAT-3 and PI3K inhibitors abrogated these protective effects, confirming the central role of these pathways. Importantly, the magnitude of urinary glucose excretion did not correlate with infarct size reduction, indicating that glucose lowering via SGLT2 inhibition alone is insufficient for cardioprotection in this model.

These findings challenge the presumption of a uniform class effect for SGLT2 inhibitors and suggest that off-target or ancillary pharmacological actions—such as engagement of mitochondrial and prosurvival signaling—may distinguish individual agents.

Comparison with Existing Internal Articles

Internal reviews and workflow guides provide complementary perspectives on the utility of PF-04971729 (ertugliflozin) in diabetes and renal glucose transport research. For example, one resource highlights ertugliflozin's unmatched SGLT2 selectivity and robust pharmacokinetics, making it a preferred tool for dissecting the SGLT2-mediated glucose transport pathway and troubleshooting transporter-specific effects. Another article (mechanistic analysis) expands on ertugliflozin's translational relevance, particularly its roles in glucose reabsorption inhibition and mucosal repair.

However, the present reference study adds crucial nuance: while the selectivity and pharmacodynamic efficacy of ertugliflozin are confirmed, its cardioprotective effects in the acute I/R injury model are less pronounced than those of other inhibitors at equivalent doses. This divergence underscores the need for careful interpretation of preclinical cardiovascular endpoints, especially when extrapolating findings from diabetes-focused models to broader indications.

Limitations and Transferability

Several caveats merit consideration. First, the study was conducted in healthy, non-diabetic mice; metabolic and inflammatory milieus in diabetes or heart failure patients may modulate drug responses. Second, the observation period was limited to acute I/R injury. Chronic dosing, comorbidities, and complex clinical scenarios may yield different results. Third, while molecular pathway analyses are robust, the precise reasons for the dose-dependent effect of ertugliflozin remain to be elucidated. These findings should not be overgeneralized to all SGLT2 inhibitors or patient populations without further validation.

Protocol Parameters

• Drug dosing: Oral administration of SGLT2 inhibitors for 7 days prior to ischemia; 10 mg/kg/day for empagliflozin, dapagliflozin, and ertugliflozin (PF-04971729), with an additional cohort receiving ertugliflozin at 20 mg/kg/day.
• Ischemia/reperfusion induction: 30 min LAD occlusion followed by 120 min reperfusion in anesthetized C57BL/6 mice.
• Urinary glucose measurements: 24-hour urine collection for glucose quantification to verify SGLT2 inhibition.
• Mechanistic assays: Mitochondrial respirometry and proteomic analysis of ischemic myocardium; pharmacological inhibition of STAT-3 and PI3K signaling to delineate pathways.
• Practical suggestion: For glucose reabsorption inhibition or renal glucose transport study models, consider a range of 1–10 mg/kg/day, adjusting for mouse strain and research endpoint.

Why this cross-domain matters, maturity, and limitations

This research bridges diabetes mellitus research and cardiovascular disease by interrogating the SGLT2-mediated glucose transport pathway in the context of acute myocardial injury. The maturity of the evidence base for SGLT2 inhibitors in diabetes is well established; however, their precise role and mechanistic basis for cardiovascular protection—especially outside of hyperglycemic states—remain incompletely defined. The reference study advances this field by delineating context- and molecule-specific effects, yet highlights the need for additional work in disease-relevant models and in understanding off-target mechanisms.

Research Support Resources

To support experimental workflows in glucose reabsorption inhibition, renal glucose transport, and cardiovascular disease models, researchers can utilize Ertugliflozin (PF-04971729, SKU A3715) from APExBIO. This compound offers high SGLT2 selectivity and well-characterized pharmacokinetics, making it suitable for mechanistic studies in both diabetes and translational cardiovascular contexts. Practical information on solubility, storage, and dosing can be found in the product dossier and related laboratory protocols.